Escitalopram in the treatment of anxiety symptoms associated with depression

Depression and Anxiety

Volumn 24, Issue 1, 2007, Pages 53-61

  Bandelow, Borwin ^a   Andersen, Henning F ^b   Dolberg, Ornah T ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b H LUNDBECK A S   (Denmark)

Author keywords

Anxiety; Escitalopram; Hamilton Anxiety Rating Scale for Anxiety; Hamilton Depression Rating Scale; Major depressive disorder; Montgomery sberg Depression Rating Scale

Indexed keywords

ESCITALOPRAM; PLACEBO; ZALEPLON; ZOLPIDEM;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY;

EID: 33847131950     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20141     Document Type: Article

References (43)

1. Bandelow B. 2003. Epidemiology of depression and anxiety. In: Kasper S, den Boer JA, Sitsen AJM, editors. Handbook on depression and anxiety. New York: Marcel Dekker. p 49-68.
2. Belzer K, Schneier FR. 2004. Comorbidity of anxiety and depressive disorder: Issues in conceptualization, assessment, and treatment. J Psychiatr Pract 10:296-306.
3. Bolton D, Luckie M, Steinberg D. 1995. Long-term course of obsessive-compulsive disorder treated in adolescence. J Am Acad Child Adolesc Psychiatry 34:1441-1450.
4. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. 1996. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 153:1293-1300.
5. Burke Wf, Gergel I, Bose A. 2002. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
6. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. 2002. Achieving remission with veniafaxine and fluoxetine in major depression: Its relationship to anxiety symptoms. Depress Anxiety 16:4-13.
7. De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, Ervard JL, Linkowski P, Fossion P, Leyman S, Mignon A. 2002. Veniafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5:115-120.
8. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. 2003. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 18:53-61.
9. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. 2000. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. J Clin Psychiatry 61:863-867.
10. Fawcett J. 1992. Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry 53(Suppl):9-13.
11. Fawcett J, Kravitz HM. 1983. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 44:8-11.
12. Goodman WK, Bose A, Wang Q. 2005. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161-167.
13. Grunhaus L, Harel Y, Krugler T, Pande AC, Haskett RF. 1988. Major depressive disorder and panic disorder: Effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol 11:454-461.
14. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
15. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
16. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W. 2000. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 57:76-82.
17. Hyttel J, Bogeso KP, Perregaard J, Sánchez C. 1992. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88:157-160.
18. Kasper S, Stein DJ, Loft H, Nil R. 2005. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222-226.
19. Kaufman J, Charney D. 2000. Comorbidity of mood and anxiety disorders. Depress Anxiety 1:69s-76s.
20. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. 1996. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. Br J Psychiatry 168(Suppl):17-30.
21. Lader M, Stender K, Bürger V, Nil R. 2004. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo controlled, fixed-dose study. Depress Anxiety 19:241-248.
22. Lepola UM, Arato M, Zhu Y, Austin C. 2003a. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64:654-662.
23. Lepola UM, Loft H, Reines EH. 2003b. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18: 211-217.
24. Lepola UM, Wade A, Andersen HF. 2004. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155.
25. Montgomery SA, Åsberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
26. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. 2005. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278.
27. Möller H-J. 2002. Anxiety associated with comorbid depression. J Clin Psychiatry 63:22s-26s.
28. Murphy JM, Horton NJ, Laird NM, Monson RR, Sobol AM, Leighton AM. 2004. Anxiety and depression: A 40-year perspective on relationships regarding prevalence, distribution, and comorbidity. Acta Psychiatr Scand 109:355-375.
29. Ninan PT, Ventura D, Wang J. 2003. Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association, May 17-22, San Francisco, CA.
30. Rapaport MH, Bose A, Zheng H. 2004. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44-49.
31. Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH. 1997. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 58:112-118.
32. Roy-Byrne PP, Stang P, Wittchen HU, Üstün B, Walters EE, Kessler RC. 2000. Lifetime panic-depression comorbidity in the National Comorbidity Survey: Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176:229-235.
33. Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, Davis S, Keller M. 2001. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13:18-27.
34. Sánchez C. 2003. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464:155-158.
35. Sánchez C, Gruca P, Bien E, Papp M. 2003a. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75: 903-907.
36. Sánchez C, Gruca P, Papp M. 2003b. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470.
37. Sánchez C, Kreilgaard M. 2004. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398.
38. Silverstone PH, Salinas E. 2001. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62:523-529.
39. Stahl SM, Gergel I, Li D. 2003. Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327.
40. van Valkenburg C, Akiskal HS, Puzantian V, Rosenthal T. 1984. Anxious depressions: Clinical, family history, and naturalistic outcome-comparisons with panic and major depressive disorders. J Affect Disord 6:67-82.
41. Vollrath M, Angst J. 1989. Outcome of panic and depression in a seven-year follow-up; Results of the Zurich study. Acta Psychiatr Scand 80:591-596.
42. Wade A, Lemming OM, Hedegaard KB. 2002. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95-102.
43. Wittchen HU, Zhao S, Kessler RC, Eaton WW. 1994. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355-364.